Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: Long-term experience

Strahlentherapie und Onkologie

Volumn 187, Issue 2, 2011, Pages 114-119

  Balduccp, Mario ^a   Chiesa, Silvia ^a   Manfrida, Stefania ^a   Rossi, Elena ^a   Za, Tommaso ^a   Frascino, Vincenzo ^a   De Bari, Berardino ^b   Hohaus, Stefan ^a   Cellini, Francesco ^c   Mantini, Giovanna ^a   D'Agostino, Giuseppe Roberto ^a   Gambacorta, Maria Antonietta ^a   Leone, Antonello ^a   Valentini, Vincenzo ^a   De Stefano, Valerio ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Pain relief; Plasma cell neoplasm; Radiotherapy; Recalcification

Indexed keywords

ZOLEDRONIC ACID; CALCIUM;

ADULT; AGED; ANALGESIA; ARTICLE; BLOOD TOXICITY; BONE ATROPHY; BONE MINERALIZATION; BONE PAIN; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RELAPSE; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEGAVOLTAGE RADIATION; MULTIPLE MYELOMA; NUMERICAL RATING SCALE; PAIN ASSESSMENT; PHARYNX DISEASE; PLASMACYTOMA; RADIATION DOSE; RADIATION SICKNESS; RATING SCALE; SKIN TOXICITY; BONE DENSITY; BONE TUMOR; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; FOLLOW UP; METABOLISM; METHODOLOGY; MIDDLE AGED; OSTEOLYSIS; PALLIATIVE THERAPY; PATHOLOGY; RADIATION EXPOSURE; RADIATION INJURY;

ADULT; AGED; BONE DENSITY; BONE NEOPLASMS; CALCIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; OSTEOLYSIS; PALLIATIVE CARE; PLASMACYTOMA; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; YOUNG ADULT;

EID: 79954427850     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2155-9     Document Type: Article

References (34)

1. Adamietz IA, Schober C, Schulte RW, et al. Palliative radiotherapy in plasma cell myeloma. Radiother Oncol 1991;20:111-6.
2. Berenson JR , Hillner BE, Kyle RA, et al. American Society of Clinical Oncology Bisphosphonates Expert Panel American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma. J Clin Oncol 2002;20:3719-36. (Pubitemid 34983232)
3. Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiother Oncol 1999;52:111-21
4. Bruno B, Boccadoro M, Palombo A, et al. Mieloma multiplo e neoplasie plasmacellulari. In: Bonadonna G (ed) Medidna Oncologica, 7th edn. Milano, Masson, 2003:1441-8.
5. Chak LY, Cox RS, Bostwick DG, et al. Solitary plasmacytoma of bone: treatment, progression, and survival. J Clin Oncol 1987;5:1811-5. (Pubitemid 18020847)
6. Chow E, Doyle M, Li K, et al. Mild, moderate or severe pain categorized by patients with cancer with bone metastases. J of Pall Medicine 2006; 9:850-4. (Pubitemid 44289906)
7. Chow E, Hoskin PJ, Wu J, et al. A phase III International randomised trial comparing single with multiple fraction for Re-irradiation of Painful Bone Metastases: National Cancer Institute of Canada Clinical Trials Grops (NCICCTG) SC 20. Clin Oncol 2006;18:125-8. (Pubitemid 43169140)
8. Chow E, Wu JS, Hoskin P, et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 2002;64:275-80. (Pubitemid 35254020)
9. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
10. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76. (Pubitemid 32452017)
11. Cox JD, Stetz J, Pajak TF et al. Toxia'ty criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
12. Criteria for the classification of monoclonal gammopathies multiple myeloma and related disorders: a report of the International Myeloma Working Group Br J Haematol 2003;121:749-57.
13. Dores GM, Landgren O, McGlynn KA, et al. Plasmocytoma of bone, extramedullary plasmocytoma, and multile myeloma : incidence and survival in the United States, 1992-2004. Br J Haematol 2008;144:86-94.
14. Frassica D, Frassica FJ, Schray MF, et al. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys 1989;16:43-8. (Pubitemid 19045333)
15. Freundt K, Meyners T, Bajrovic A, et al. Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively adioresistant tumors. Strahlenther Onkol. 2010;186:218-23.
16. Gertz MA, Chen MG (2007) Multiple myeloma and other plasma cell neoplasms. In: Gunderson LL (ed) Clinical Radiation Oncology. 2nd edn, Philadelphia: Churchill Levingstone Elsevier 2007:1753-72.
17. International Commission on Radiation Units and Measurements. ICRU Report 50. Prescribing, recording, and reporting photon beam therapy. Bethesda, MD: ICRU, 1993.
18. International Commission on Radiation Units and Measurements. ICRU Report 62. Prescribing, recording, and reporting photon beam therapy (Supplement to ICRU Report 50). Bethesda, MD: ICRU, 1999.
19. Wu JS-Y, Wong R, Johnston M, Bezjak A, et al. Meta-analysis of dose-frac- tionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003;55:594-605. (Pubitemid 36170000)
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
21. Kowing S, Budach V. Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther Onkol 1999;175:500-8.
22. Leigh BR, Kurtts TA, Mack CF, et al. Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys 1993;25:801-4. (Pubitemid 23123383)
23. Mill WB, Griffith R. The role of radiation therapy in the management of plasma cell tumours. Cancer 1980;45:647-652 (Pubitemid 10174602)
24. Momm F, Lingg S, Xander C, et al. The situation of radiation oncology patients' relatives. A stocktaking. Strahlenther Onkol 2010;186(6):344-50.
25. Mose S, Pfitzener D, Rahn A, et al. Role of radiotherapy in the treatment of multiple myeloma. Strahlenther Onkol 2000;176:506-12.
26. Mücke R, Seegenschmiedt MH, Heyd R, et al. Radiotherapy in painful gonarthrosis. Results of a national patterns-of-care study. Strahlenther Onkol 2010;186:7-17.
27. Munshi NC, Tricot G, Barlogie B. Plasma cell neoplasm. In: De Vita VT (ed) Principles and Practice of Oncology, 6th edn, Lippincott Williams & Wilkins Publishers, 2001:1816-37.
28. Perez CA, Brady LW, Halperin EC, et al. Principles and Practice of Radiation Oncology, Fourth Edition. Philadelphia PA, Lippincott Williams and Wilkins, 2004.
29. Roos DE, Turner SL, O'Brien PC, et al. TROG 96.0B Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05) Radiother Oncol 2005;75(1):54-63. (Pubitemid 40616795)
30. Stolting T, Knauerhase H, Klautke G, et al. Total and single doses influence the effectiveness of radiotherapy in palliative treatment of palsmocytoma. Strahlenther Onkol 2008;184:465-72.
31. Souchon R, Wenz F, Sedlmayer F, et al. DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: bone metastases and metastatic spinal cord compression (MSCC). Strahlenther Onkol 2009;185(7):417-24.
32. Vakaet LA, Boteberg T. Pain control by ionizing radiation of bone metastasis. Int J Dev Biol Phys 2004;48:599-606. (Pubitemid 39360410)
33. Van Der Linden YM, Lok JJ, Steenland E, et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 2004;59:528-37. (Pubitemid 38622611)
34. Vassiliou V, Tselis N, Kardamakis D. Osteonecrosis of the jaws: clinicopathologic and radiologic characteristics, preventive and therapeutic strategies. Strahlenther Onkol 2010;186:367-73.